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The “Bone Involvement in Arthritis” International Meeting was first held in
Venice, in 2004, with the objective of bringing together distinguished
international experts in the fields of bone metabolism and rheumatic
diseases to discuss emerging knowledge regarding the interplay between
rheumatic diseases and the bone tissue. The growing interest and the
continuous progresses on the topic led to the organization of six other
meetings, which included several different established clinicians and/or
researchers.
Since its origin, the meeting focused on the interactions between the
bone tissue, the immune system and the cartilage in osteoarthritis,
rheumatoid arthritis and spondyloarthropathies, always considering the
two sides of the coin: the basic and clinical. In past years, as well as this
year, specific sessions were dedicated to osteoarthritis (OA), rheumatoid
arthritis (RA) and ankylosing spondylitis, respectively, with a starting
session considering the general aspects of the topic. In this context, the
bone damage as an early manifestation of arthritides, the systemic
skeletal involvement in RA, the crucial role played by subchondral bone
in the pathogenesis and progression of OA, the pathophysiology of
glucocorticoids damage on the bone tissue, and the potential beneficial
effects of newly approved agents such as bisphosphonates and biologics,
but not only, were discussed.
In 2011, the meeting has been named, for its first time, “Osteo-
Rheumatology”, thus implying the necessity of giving a more clear
definition to topics presented and the issues raised. Even this year, experts
in bone and rheumatic diseases interacted to improve our knowledge
regarding the bone involvement in arthritis and to raise issues to be
addressed in the future.
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Several pharmacological agents [bisphosphonates (BPs), SERMs, teriparatide,
PTH 1-84, strontium ranelate, denosumab] have been approved worldwide
for the prevention of fragility fractures in patients at risk. In pivotal
randomized-controlled trials (RCTs), these drugs demonstrated to reduce the
incidence of new vertebral fractures, and, in some cases, of new non-
vertebral and hip fractures, in women and men with primary and
glucocorticoid-induced osteoporosis, with a good profile of safety and
tolerability. Most of the studies, however, were designed to assess the
efficacy and safety of these drugs for 3 to 5 years, and only few of them
extended over 5 years (BPs).
Although RCTs extension studies were carried out in smaller samples
compared to the original baseline populations enrolled, their results
support the sustained beneficial effects on skeletal metabolism of
alendronate (10 years), zoledronate (6 years) and risedronate (7 years) on
the long term. Due to their pharmacological properties, BPs have also
demonstrated to prolong their efficacy after discontinuation in specific
subgroups of patients.
In recent years, some concerns have been raised about long-term safety
of BPs, due to “unexpected” rare adverse events (AEs) potentially
associated with their use (atypical fractures, ONJ and esophageal cancer).
Indeed, a cause-effect relationship has not been yet demonstrated.
However, given the dramatic implications of these rare AEs, a drug-free
holiday should be considered in patients treated for more than 5 years
with BPs, after an accurate evaluation of risks and benefits.
Regarding the recently approved anti-osteoporotic agents less
information are available. Denosumab have been shown to produce a
sustained increase of bone mineral density over 8 years of treatment, and
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treatment. Similar results have been described also for strontium ranelate.
In this context, studies are warranted to clarify when and for how long a
drug-free holiday should be considered in patients receiving BPs.
Moreover further trials are needed to clarify the long-term safety and
beneficial effects of the newly approved agents (denosumab, strontium
ranelate).
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Knee OA is thought to be a largely mechanically-driven disease. Pertinent
to this, bone is a dynamic tissue that adapts to loads by remodeling to
meet its mechanical demands (Wolff’s Law) [1,2]. As such, it is not
surprising that bone changes, such as increased tibial plateau area and
bone turnover, occur early in OA [3,4]. Recently, MRI-based 3D bone shape
has been shown to track concurrently with OA onset, and to predict
incidence of radiographic knee OA 12 months before its onset [5]. Further,
in radiographically normal tibiofemoral knee joints, subchondral bone
changes, such as bone marrow lesions (BMLs) on MRIs, are common.
Although MRIs allow direct visualization and morphologic evaluation of joint
tissues not otherwise discernible on x-ray, their specific pathologies need to
be examined by direct evaluation to gain further pathophysiologic insight.
BMLs adjacent to the subchondral plate have been shown to have increased
bone volume fraction and increased trabecular thickness, but reduced tissue
mineral density (i.e., hypomineralized) [6], consistent with OA being
associated with increased bone turnover. BMLs may render these areas
mechanically compromised and susceptible to attrition. Indeed, BMLs are
strongly associated with occurrence of subchondral bone attrition (SBA) [7].
Both subchondral bone abnormalities are associated with cartilage loss as
well [8,9]. In keeping with knee OA being mechanically-driven, meniscal
pathology, often the result of injury, is associated with new and enlarging
BMLs [10]. Further, malalignment is associated with both BMLs and SBA
[11,12].
The contributions of these structural abnormalities to the clinical
manifestations of knee OA are becoming better understood. While it is
widely thought that there is a structure-symptom discordance in knee OA,
such observations do not take into account all of the potential factors that
can contribute to between-person differences in the pain experience [13].
Recent work that used novel methodology to overcome this problem has
demonstrated that pain fluctuation is associated with changes in BMLs, as
well as synovitis and effusion [14]. SBA has also been associated with knee
pain [15], but the relationship of osteophytes to pain has been conflicting.
A challenge that remains in studying the specific contribution of
pathologic features of OA to pain is t h ec o - e x i s t e n c eo fm u l t i p l eM R I
abnormalities, making it difficult to identify individual pathologic features’
effects.
Understanding the pathophysiologic sequences and consequences of OA
pathology will guide rational therapeutic targeting. Importantly, rational
treatment targets also require understanding what particular structures
contribute to pain as pain is the reason patients seek medical care.
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Inherited autoinflammatory syndromes (IAS) are a group of recently
identified monogenic diseases characterized by recurrent episodes of
systemic inflammation.
Muckle-Wells Syndrome, Familial Cold Autoinflammatory Syndrome and
Chronic Infantile Neurological Cutaneous and Articular Syndrome are IAS
due to mutations in a single gene, CIAS1 (cold-induced autoinflammatory
syndrome 1, or NALP-3), encoding a protein called cryopyrin which is an
essential component of an intracellular multiprotein complex named
inflammasome, that play a crucial role in the production and secretion of
interleukin (IL)-1 These diseases are characterized by excessive production of
IL-1 and have a dramatic response to IL-1 inhibition.
More recently, IL-1 inhibition has also been shown to be effective in another
AID (TNF-receptor associated periodic syndrome or TRAPS) as well as in
other conditions such as systemic juvenile idiopathic arthritis and recurrent
idiopathic pericarditis. This has suggested that also these two last diseases
may represent autoinflammatory conditions.
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chondroprogenitor cell differentiation. The chondrocytes then form the
cartilage at the end of the opposing bones with the intervening interzones
formed during cavitation or they undergo proliferation, terminal
differentiation to chondrocyte hypertrophy, and apoptosis in a process
termed endochondral ossification, whereby the hypertrophic cartilage is
replaced by bone. A similar sequence of events occurs in the postnatal
growth plate and leads to rapid growth of the skeleton. Human adult
articular cartilage is a complex tissue of matrix proteins that varies from
superficial to deep layers and from loaded to unloaded zones. A major
challenge to efforts to repair cartilage by stem cell-based and other tissue
engineering strategies is the inability of the resident chondrocytes to lay
down new matrix with the same properties as it had when it was formed
during development. This is particularly true of the collagen network,
which is susceptible to cleavage once the proteoglycans are depleted.
Thus, understanding and comparing the mechanisms of cartilage
remodeling during development, osteoarthritis (OA), and aging may lead
to more effective strategies for preventing cartilage damage and
promoting repair. To identify and characterize mediators of cartilage
remodeling common to these processes, we are using culture models of
primary human and mouse chondrocytes and cell lines and mouse models
to manipulate and compare gene expression with complementary
approaches. MMP-13, the major type II collagen-degrading collagenase, is
regulated by both stress and inflammatory signals that not only contribute
to irreversible joint damage (progression) in OA, but importantly, also to
the initiation/onset phase, wherein chondrocytes in articular cartilage leave
their natural growth - and differentiation-arrested state. We and other
investigators have found that there are common mediators of these
processes in human OA cartilage and from early through late stages of OA
in mouse models, including the surgical models (good matrix with
abnormal loading) and the genetic models during aging (bad matrix with
normal loading). We are validating our in vitro analyses of the signaling
and transcriptional mechanisms that determine the expression and
activities of these mediators by in vivo analyses of the consequences of
knockout or transgenic overexpression of these genes in mouse models. In
current studies, we are examining the epigenetic mechanisms and using
proteomics and genomics approaches to map the signaling networks and
microRNA targets that impact on gene expression programs during the
onset and progression of OA in both human and murine cartilage. Since
the chondrocytes in adult human cartilage are normally quiescent and
maintain the matrix in a low turnover stated, understanding how they
undergo phenotypic modulation and promote matrix destruction and
abnormal repair in OA may to lead to identification of critical targets for
therapy to block cartilage damage and promote effective cartilage repair.
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Osteoarthritis (OA) emerges of the inharmonious functioning of joint
tissues, particularly subchondral bone (SB) and articular cartilage that are
two mechanically and biologically intertwined tissues [1]. Thus,
biomechanical, biochemical and/or genetic alterations affecting any joint
tissue may cause anomalous intra-articular stresses and subsequent tissue
damage associated to a failure of repair [2]. Specific anatomical regions
have been described in the bone underlying joint cartilage, including the
subchondral cortical plate, subchondral trabecular bone and sub-articular
bone [3]. Each region likely contributes differently to cartilage pathology.
However, a lack of clear boundaries between these tissues by current
imaging techniques generates some confusion in their study and thorough
research will help to improve our understanding of SB properties. In
addition, bone at the joint margins is markedly active since is the site of
osteophyte development in OA. The close relationship between SB and
joint cartilage evokes an unanswered question with valuable therapeutic
implications [4]. In this context, the relationship among SB microstructure
and remodeling, and cartilage destruction becomes important.
Yet, it remains controversial whether SB alterations precede the cartilage
damage or they further appear during the evolution of the disease. In fact,
SB remodeling abnormalities, especially increased bone turnover, have
been detected early in the evolution of some forms of OA in animal
models [5,6] and humans [7,8]. On the other hand, OA and systemic
osteoporosis (OP) share a paradoxical relationship, being probable that
high as well as low bone mass conditions result in induction and/or OA
progression [4]. Interestingly, improving SB integrity showed to reduce the
progression of cartilage damage in an animal model of OA preceded by
OP [9]. Therefore, both bone mass phenotypes may be considered risk
factors for OA initiation. The presence of other risk factors such as skeletal
shape abnormalities, joint overload or obesity may have a synergistic
effect for OA initiation. In addition, inflammatory mediators released by the
articular cartilage may lead to SB loss by increasing bone remodeling in
OA. Accordingly, OA treatment goals must consider the improvement of
SB integrity. This therapeutic approach should be individualized
depending on the patient BMD status and OA phenotype, and
subsequently the use of drugs should also be individualized for each
patient [10]. Recent findings suggest that the same drugs could be useful
for treating simultaneously both processes, at least in a subgroup of
patients with OA and concomitant OP.
References
1. Goldring MB, Goldring SR: Articular cartilage and subchondral bone in
the pathogenesis of osteoarthritis. Ann NY Acad Sci 2010, 1192:230-237.
2. Lane NE, Brandt K, Hawker G, et al: OARSI-FDA initiative: defining the
disease state of osteoarthritis. Osteoarthritis Cartilage 2011, 19:478-482.
3. Burr DB: Anatomy and physiology of the mineralized tissues: role in the
pathogenesis of osteoarthrosis. Osteoarthritis Cartilage 2004, 12(Suppl A):
S20-S30.
4. Herrero-Beaumont G, Roman-Blas JA, Largo R, et al: Bone mineral density
and joint cartilage: four clinical settings of a complex relationship in
osteoarthritis. Ann Rheum Dis 2011, 70:1523-1525.
5. Pastoureau PC, Chomel AC, Bonnet J: Evidence of early subchondral bone
changes in the meniscectomized guinea pig. A densitometric study
using dual-energy X-ray absorptiometry subregional analysis.
Osteoarthritis Cartilage 1999, 7:466-473.
6. Hayami T, Pickarski M, Zhuo Y, et al: Characterization of articular cartilage
and subchondral bone changes in the rat anterior cruciate ligament
transection and meniscectomized models of osteoarthritis. Bone 2006,
38:234-243.
7. Day JS, Ding M, van der Linden JC, et al: A decreased subchondral
trabecular bone tissue elastic modulus is associated with pre-arthritic
cartilage damage. J Orthop Res 2001, 19:914-918.
8. Hochberg MC, Lethbridge-Cejku M, Scott WW Jr, et al: Upper extremity
bone mass and osteoarthritis of the knees: data from the Baltimore
Longitudinal Study of Aging. J Bone Miner Res 1995, 10:432-438.
9. Bellido M, Lugo L, Roman-Blas JA, et al: Improving subchondral bone
integrity reduces progression of cartilage damage in experimental
osteoarthritis preceded by osteoporosis. Osteoarthritis Cartilage 2011,
19:1228-1236.
10. Castañeda S, Roman-Blas JA, Largo R, et al: Subchondral bone as a key
target for osteoarthritis treatment. Biochem Pharmacol 2011, 83:315-323.
A7
Cross-talk between subchondral bone and articular cartilage in
osteoarthritis
Steven R Goldring
Hospital for Special Surgery, New York 10021, NY, USA
E-mail: goldrings@hss.edu
Arthritis Research & Therapy 2012, 14(Suppl 2):A7
The interest in the relationship between articular cartilage and the
structural and functional properties of peri-articular bone relates to the
intimate contact that exists between these tissues in diarthrodial joints.
Much of the interest and continuing controversy regarding the relationship
between these tissues dates back to the original suggestion by Radin and
Rose that alterations in the mechanical properties of subchondral bone
could adversely affect the functional state of chondrocytes and the
integrity of the overlying cartilage. They hypothesized that the
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was secondary to an initial increase in subchondral bone stiffness induced
by repetitive mechanical loading. Numerous approaches have been used
to establish that the changes in periarticular bone occur very early in the
development of OA. Although chondrocytes also have the capacity to
modulate their functional state in response to loading, the capacity of
these cells to repair and modify their surrounding extracellular matrix is
relatively limited in comparison to the adjacent subchondral bone. This
differential adaptive capacity likely underlies the more rapid appearance of
detectable skeletal changes in OA in comparison to the articular cartilage.
Given the intimate mechanical and biological interaction between the
articular cartilage and subchondral bone it is likely that alterations in the
composition and/or structural organization of either tissue will modulate
the properties and function of the other joint component. An additional
factor that affects the interaction between these tissues is the gradual
expansion of the zone of calcified cartilage and advancement of the
tidemark that occurs with aging and progression of OA and contributes to
overall thinning of the articular cartilage. The precise mechanisms involved
in this process have not been definitively established and could include
the release of pro-angiogenic factors from chondrocytes in the deep zones
of the articular cartilage that have undergone hypertrophy and/or the
influences of microcracks that have initiated focal remodeling in the
calcified cartilage in an attempt to repair the microdamage. In addition,
this process markedly increases the mechanical stresses in the deep zones
of the cartilage matrix, which likely contributes to the acceleration in OA
cartilage deterioration. In summary, there is the need for further studies to
define the pathophysiological mechanisms involved in the interaction
between subchondral bone and articular cartilage and for applying this
information to the development of therapeutic interventions to improve
the outcomes in patients with OA.
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Hand osteoarthritis (OA) is not one disorder, but a heterogeneous group
of disorders. Erosive HO (EOA) is a radiographic subset of hand OA and
defined on the basis of radiographic central erosions and collapse of the
subchondral bone plate. At the moment it is unknown whether EOA
comprises a separate disease entity with specific risk factors and
pathogenesis or a more severe stage of hand OA.
EOA is a rather uncommon subset of OA. In the general population a
prevalence of EOA in the interphalangeal joints (IPJs) of approximately
3% was estimated in adults aged 55 years and over. In the population
with hand pain or with symptomatic hand OA the prevalence estimates
were around 7% and 10%, respectively. However in a population with
symptomatic hand OA from secondary care, the prevalence of EOA raised
to 25%.
The presence or absence of specific risk factors for EOA could learn
whether EOA is a separate disease entity or a severe stage of hand OA.
The first step in this research deals with heritable factors. Several studies
suggest that EOA is heritable. Within patients with hand OA, several
genetic factors are demonstrated to be associated with EOA when
compared to non-erosive hand OA, but further replication of found
results is needed.
EOA is a highly clinical relevant subset, since EOA leads to a higher
clinical burden and worse outcome than non-erosive hand OA. Patients
with EOA report more pain and functional limitations, worse hand
mobility, less satisfaction with hand function and aesthetics than those
with non-erosive hand OA. However patients with EOA have also more
nodes, which were also found to be a determinant of clinical outcome.
Taking in account nodes, only hand mobility and patient satisfaction
remained different between the groups.
In the pathophysiology of EOA inflammation could be important. Already
since 1972 it is noted that inflammation is involved in EOA, as also
witnessed by histology of synovial biopsies of erosive DIPJs and PIPJs in
an inflammatory stage, showing intense proliferative synovitis
indistuinguishable from rheumatoid arthritis. Recently the presence and
role of inflammation is further investigated by ultrasound and MRI
studies. Moreover, ultrasound studies showed that not only in erosive but
also in non-erosive joints in EOA more power Doppler signal and effusion
is seen in comparison to joints in non-erosive hand OA, suggesting an
underlying cause for erosive evolution.
Another important observation is that erosions are more frequently
present in hand OA than based on radiography when using ultrasound.
The meaning of erosions only detected on MRI and ultrasound has to be
elucidated.
In conclusion, EOA is a highly clinical relevant subset of hand OA.
Whether it is a separate disease entity is at the moment unknown, but
needs further study. Inflammation seems of importance, already in the
pre-erosive stages. Further research in this hand OA subset could lead to
new treatments for patients with EOA.
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Given the strict link between structural damage and disability, the
prevention of disease progression can be considered the ultimate goal of
every rheumatoid arthritis (RA) treatment strategy. At least 4 imaging
tools for measuring damage progression in RA are now available: x-rays,
ultrasounds, MRI, and CT scan. However, so far in main randomized
clinical trials (RCTs) radiography was used as the gold standard for
structural damage assessment. Several different radiographic scoring
methods have been proposed, but nowadays the most widely used are
the Sharp method and its subsequent modifications proposed by van der
Heijde and Genant. A recently published paper has demonstrated a
strong correlation between various scoring systems. Sixteen main
registrative RCTs evaluating the performance of biologic agents in
slowing RA structural damage can be found in the literature. Overall, all
biotherapies demonstrated a significantly lower damage progression than
methotrexate (MTX) used both in monotherapy (adalimumab in the
PREMIER and etanercept in the TEMPO trials) and in combination with
MTX, with the exception of golimumab in the GO-FORWARD trial. So far,
no RCTs head-to-head comparing various biologic agents have been yet
performed, and indirect comparisons may have several important
limitations regarding study design, study population selection, and choice
of used radiographic scoring method. Standardization of scores generated
with different scoring systems, matching clinical trials by disease duration
and previous treatments, and evaluating the annual estimated
progression in each trial may be crucial key factors in order to better
compare data coming from different RCTs. Applying this comparison
approach, the impact of various biologic drugs in slowing x-ray
progression seems to be similar in early RA. On the contrary, the
differences in study population characteristics are too marked in late RA
for an adequate comparison of biologics performance in this clinical
condition. Anyway, the overall impact of biotherapies versus MTX on
damage progression seems to be similar in early and in late RA patients.
The results in the open extension phase of some previously mentioned
RTCs seem to confirm the positive effect of biologic drugs on structural
damage in long-term evaluation. A few data coming from RCTs (TEMPO
trial) suggest the possibility of repairing bone erosions in patients treated
with TNF blockers. Preliminary data on denosumab suggest a possible
role of this RANK-L inhibitor in the treatment of RA, mainly as a part of a
combination therapy in association with synthetic DMARDs.
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Osteoarthritis is the most common joint disease and a major cause of
disability. The changes in the lubricating properties of synovial fluid lead to
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the joints, called Viscosupplementation, improves the biochemical
properties of synovial fluid (SF) in osteoarthritis (OA) joints. The clinical
effect is pain relief and someone has hypothesized a disease modifying
activity . Intra-articular (IA) hyaluronan therapy has been used in the
treatment of symptoms associated with OA of the knee and other joints
with a very favourable safety profile. The high concentration of HA in SF is
essential for normal joint function. Balazs and Denlinger were the first to
suggest that the favourable effects of IA HA therapy in OA was related to
the SF rheological properties restoration. Many subsequent studies have
supported that IA HA therapy could be a symptom-modifying approach.
The hypothesis that HA could bind specific receptors is now widely
accepted. The cluster determinant 44 (CD44), the intracellular adhesion
molecule-1 (ICAM-1) and hyaluronate-mediated motility receptor (RHAMM)
expressed in many cells, are some of those implicated in the process. The
binding of HA with its specific receptors has been reported to trigger
various intracellular signals such as cytokine release and stimulation of cell
cycle proteins. The consequences of these interactions is to stimulate cell
functional activities such as cell migration and proliferation. Presently,
there are several different HA products with different molecular weight
available for injection. Several meta-analysis have reviewed clinical trials
published in the last years using different HA preparation that support the
benefit and safety of repeated treatment with IA HA. Many trials indicate
that sodium hyaluronate is well tolerated and as effective after multiple
courses of treatment as it is after a single course. Other informations state
that viscosupplementation is an effective treatment for patients with knee
OA who have ongoing pain or are unable to tolerate conservative
treatment or joint replacement. Viscosupplementation appears to have a
slower onset of action than intra-articular steroids, but the effect seems to
last longer. Viscosupplementation is an effective treatment for OA of the
knee with beneficial effects on pain, function and patient global
assessment at different post injection periods but especially at the 5 to
13 week with a dramatic effect on the reduction of NSAIDs monthly
consumption. In some analyses viscosupplements were comparable in
efficacy to systemic forms of treatment, with more local reactions but
fewer systemic adverse events. In other analyses HA products had more
prolonged effects than IA corticosteroids. Overall, the aforementioned
analyses support the use of the HA class of products in the treatment of
knee OA. In one systematic review intra-articular hyaluronic acid has not
been proven clinically effective and may be associated with minimal and
transient risk of adverse events. The heterogeneity of these studies limits
definitive conclusions on different treatment regimen with different
molecular weight HA but, in our opinion, we think that generally HA
products may determine a reduction of symptoms by 40%. Few data exists
in literature about the viscosupplementation of hip OA, the second most
common site of the disease after the knee. The intra-articular injection of
the hip is not as easy as for the knee, mainly for anatomical features of the
joint and the proximity of “sensitive” structures such as the femoral artery
and nerves. Even though hip injection may be performed “blindly”,
nevertheless failure rate is significant and when using a slow absorbing
viscosupplement like hyaluronan the potential local complications may
jeopardize the therapeutic benefit. For such reasons, it has been suggested
to perform intra-articular injection of the hip under radiological or
ultrasound control. Although several ultrasound guidance techniques were
available we developed a personal one using an antero-superior approach.
The efficacy data, presents in literature, underline significant improvement
in pain and function as has been shown in the knee OA despite the small
size of the sample and the short period of observation have not allowed to
point out a change in the natural history of the disease. In order to confirm
these promising data large scale double blind controlled trials must be
carried out. Despite recent progress, many unresolved issues require
further study. These include the necessity to determine the relative
economic efficacy of viscosupplementation, explore the therapeutic
effectiveness and safety, clearly define the relation between molecular
weight and clinical effectiveness of the different hyaluronan products,
establish optimal dosing regiments and assess potential synergistic or
additive effects with other modalities such NSAIDs and SYSADOA. If
hyaluronan derivatives are eventually proven to have clear disease-
modifying effects, it may then be reasonable to consider their use early in
cartilage injury or disease, before the onset of syntomatic OA. Additional
well-designed randomized controlled trials with high methodological
quality are needed to resolve the continued uncertainty about the
therapeutic effects of different types of hyaluronic acid products on
osteoarthritis.
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Therapies of chronic diseases should be efficacious, convenient for the
patient and devoid of side effects. In daily practice, the risk of serious
outcomes and the preference of patients as well as the cost of the
interventions should also be considered. The pathophysiological basis of
osteoporosis provides the rationale for the use of interventions that either
reduce bone resorption and turnover or stimulate bone formation. Several
antiresorptive treatments are used in the treatment of osteoporosis but
PTH is the only anabolic therapy currently available. Evidence for efficacy
and safety from controlled studies has been obtained for up to 10 years
for antiresorptives and up to 2 years for PTH. while short-term head-to-
head studies with surrogate endpoints have also been performed. Such
studies illustrate the different mechanism of action of the two types of
interventions but do not allow any conclusions about any potential
differences in antifracture efficacy. These considerations are reflected in
recommendations of several regulatory authorities. It is also frequently
assumed that antiresorptives should be given mainly to patients with high
bone turnover while anabolics should be reserved for patients with low
bone turnover. However, analyses of the results of trials with
bisphosphonates and PTH 1-34 indicated that the antifracture efficacy of
these agents is independent of prevalent rates of bone turnover. Further
analysis of the pharmacodynamic responses to these treatments, reveal
distinct patterns with attainment or not of steady-states that provide the
basis for the design of regimens with the use of both types of therapies, in
some patients at least. Most of the studies have been performed with
bisphosphonates and PTH. Combination therapies, a common approach in
the treatment of other chronic disease, do not confer any particular
advantage compared to monotherapies, although the response may
depend on the frequency of the administration of the bisphosphonate. In
contrast, sequential therapies are very important for clinical practice and
depend on the severity of the disease and the mechanism of action of the
specific treatment. Such therapeutic approaches need to be explored
further and their efficacy in reducing fracture risk, their safety as well as
their cost-effectiveness need to be evaluated.
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Biologic agents have been used for more that twelve years in treating
rheumatoid arthritis (RA) and other rheumatic diseases. Long-term analysis
for both efficacy/effectiveness and safety is now feasible for the first anti-
TNF agents available, namely infliximab, etanercept and adalimumab.
Open-label extension studies have shown that clinical improvement is
maintained up to10 years. However, these studies include only the
patients who have sustained efficacy without the development of
significant adverse events that would cause the patient to exit the study
prior to closure. Therefore, as with any completer analysis of efficacy, the
results reported are generally positive. Furthermore, clinical trial patients
may not be representative of the entire patient population since in the
clinic setting the indications for treatment with biologic agents are not
identical to the inclusion criteria for trials. Only a minority of the patients in
the clinical setting would have been eligible for the major trials; ineligible
patients have lower baseline disease activity, more comorbidity, lower
functional status and lower response rates. Despite these data, long term
evaluation of effectiveness and safety in observational studies and
registers has shown that TNF inhibitors are still a good choice in treatment
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There is still growing insight on the links between the immune system and
bone at the anatomical, vascular, cellular and molecular level. At the
anatomical level, bone is at the inside in direct contact with the bone
marrow and at the outside with structures that are involved in chronic
inflammatory rheumatic diseases (entheses, periosteum, calcified cartilage).
At the cellular and molecular level, many bilateral cross-talks between the
immune system and bone have been described, in normal physiological
conditions and during inflammation. In addition, in the presence of bone
erosions at the sites of inflammation, direct contact is available between
the bone marrow and the joint cavity.
Bone resorption is increased in RA. This has been demonstrated by the
presence of activated osteoclasts in the pannus at the site of bone
erosions and in subchondral osteitis.
The final cellular pathway of the attack of chronic or recurrent inflammation
on bone is the recruitment and activation of osteoclasts. One of the central
molecular pathways in this process is RANK ligand/OPG. In normal
conditions, the osteoblast is the main regulator of bone resorption by this
pathway. In rheumatoid arthritis, RANK ligand is also produced by
inflammatory cells, including activated T- and B-cells, which are present in
synovitis and in subchondral osteitis. By playing a central role in erosion
formation, the osteoclast is not only responsible for functional handicap
resulting from bone destruction at long term, but also for allowing the joint
space to have direct access with subchondral bone marrow and its vast
reserve of stem cells and B-cells.
Inhibition of osteoclasts by denosumab, a humanized antibody that
selectively binds RANK ligand, has revealed that the occurrence of
erosions and peri-articular bone loss can be halted, however without
affecting synovial inflammation. This disconnect between inflammation
and bone destruction opens new ways to separately focus treatment on
inflammation and osteoclastogenesis for preventing and/or minimizing
the connection between joints and subchondral bone and bone marrow.
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The presentation describes the novel insights on the interaction between
t h ei m m u n es y s t e ma n db o n eo v e rt h el a s t1 0y e a r ,a n de x p l a i n s
molecular and cellular interactions as well as their clinical implications.
Bone is subject to a continuous remodeling process which allows an ideal
adaptation to the individual demands throughout life. This remodeling
process is based an interplay between bone forming osteoblasts and the
bone resorbing osteoclasts. Several conditions alter this balance, among
them the drop of estrogens levels after menopause is the most well
known factor, which leads to enhanced bone resorption and bone loss.
Interestingly, all different forms of inflammatory diseases such as
rheumatoid arthritis, systemic lupus erythematosus and inflammatory
bowel disease also interfere with the bone remodeling process and
precipitate bone loss and increased fracture risk.
To study this interaction between immune activation/inflammation and
the skeletal system has become a novel research discipline called
osteoimmunology. This field has gained insights into the mechanism of
inflammatory bone loss, in particular of how inflammatory cytokines like
TNF-alpha, IL1 or IL6 foster bone resorption and inhibit bone formation,
resulting in an imbalance of bone homeostasis and thereby precipitating
bone loss. Therapeutic inhibition of cytokines has yields profound
changes architecture in arthritis patients and protects the bone and in
part also the articular cartilage. Inflammatory cytokines particularly
enhance bone loss by activation of osteoclast differentiation factors such
as MCSF and RANK ligand and by molecules which interfere with bone
formation such as DKK1 and sclerostin.
The insights into molecular regulation of bone remodelling by the immune
system are thus of key interest in better understanding inflammatory
diseases such as arthritis and to shape novel therapeutic concepts. Research
in the field of osteoimmunology has a strong translational approach and
directly affects patients suffering from inflammatory diseases, in particular
arthritis, in aiming to prevent skeletal damage and loss of physical function.
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Inflammatory joint diseases like rheumatoid arthritis (RA), as well as other
rheumatic conditions such as ankylosing spondylitis and systemic lupus
erythematosus, comprise a heterogeneous group of joint disorders that are
all associated with extra-articular side effects, including bone involvement.
Disease activity, immobility and treatment with glucocorticoids are the main
factors that increase the risk of osteoporotic fractures, on top of the
background fracture risk based on, amongst others, age, body mass index
and gender. It is thought that the pathogenesis of both peri-articular and
generalized osteoporosis and local bone erosions share common pathways.
This hypothesis has been strengthened by the discovery that osteoclasts,
stimulated mostly by the receptor activator of nuclear factor kappa B ligand
(RANKL) pathway, play a central role in all of these processes.
Generalized bone loss has been documented in cross-sectional studies: a
2-fold increase in osteoporosis, defined as a T-score <−2.5 in females and
Z-score <−1 was found in 394 postmenopausal RA-patients and 192 male
RA-patients [1]. Before the introduction of biologicals, a high bone loss was
also observed in a longitudinal study in early RA: −2.4% at the spine and
−4.3% at the trochanter [2]. Against that background, it is relevant that we
investigated whether treatment with anti-TNF-a prevents loss of bone
mineral density at the spine and hip (generalized) and in the hands (local) in
patients with rheumatoid arthritis (RA) and during anti-TNF treatment [3].
102 patients with active RA, who were treated with infliximab during one
year, were included into this open cohort study. The BMD of the spine and
hip was unchanged during treatment with infliximab, whereas BMD of the
hand decreased significantly by 0.8% (p < 0.001). The BMD of the hip in
patients with an EULAR good response showed a favorable change
compared with patients not achieving such a response. This is a proof that
the usually occurring generalized bone loss in patients with RA can be
arrested by the use of aggressive antirheumatic drugs, such as anti-TNF.
Next to BMD changes upon anti-TNF, we investigated the changes in bone
markers, to elucidate the underlying mechanism of the favourable effect of
anti-TNF. Bone formation was measured by osteocalcin (OC) and bone
resorption was determined by b-isomerized carboxy terminal telopeptide
of type 1 collagen (b-CTx); osteoclast regulating proteins including the
soluble receptor activator of Nfb (s-RANKL) and osteoprotegerin (OPG)
were determined in serum using an ELISA from Immun-diagnostik. Serum
b-CTx and RANKL were both significantly decreased compared to baseline
at all time points. The decrease in b-CTx was associated to the decrease in
DAS-28 and CRP during the 0 to 14 weeks interval. No changes were
observed in serum osteocalcin and OPG. These data on bone mineral
density emphasizes that the arrested bone loss at the spine and hips can
be described to a large extent to a decrease in disease activity.
Later on, it was also shown that bone loss could be arrested in RA-patient
treated with adalimumab [4], and the favourable effects of anti-TNF on
bone markers were also observed during treatment with rituximab [5].
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Bone morphogenetic proteins (BMPs) are members of the transforming
growth factor-beta superfamily and were originally identified as proteins
that induce a full cascade of endochondral bone formation in vivo and
ectopically. We hypothesized that the BMP signaling pathway could also
play a role in the process of ankylosis that characterizes ankylosing
spondylitis and related spondyloarthritides. By over expression of noggin, a
BMP antagonist, in a dedicated mouse model of joint ankylosis, we
provided evidence for this hypothesis. Our current studies focus on the
relationship between stromal cell activation and inflammation, a link that
is essential in ankylosing spondylitis. Emerging functional and genetic
evidence further corroborates the essential role of BMPs in these
processes. BMPs can trigger different downstream signaling cascades, in
particular Smad and p38 signaling. Inhibition of p38 signaling in vivo in
the spontaneous ankylosing enthes i t i sm o d e la p p e a r st oa c c e l e r a t e
ankylosis while inhibiting in vitro chondrogenesis. Genetic analysis of
intercrosses between the susceptible DBA/1 strain and the H2 identical
Balb/c strain point towards a region containing the BMP type Ib receptor
as a factor determining genetic susceptibility. Recent clinical data suggest
that levels of BMPs are higher in patients with progressive ankylosis in
comparison with patients that show no structural progression of disease.
Taken together, these data support our hypothesis that BMP signaling is a
therapeutic target in ankylosing spondylitis.
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Osteoporosis and fractures, especially vertebral fractures, are a frequent
complication of ankylosing spondylitis, even in the early stages of the
disease. The risk of osteoporosis appears to be associated with elevated
biochemical markers of bone turnover, increased pro-inflammatory
cytokines, lower BMD, lower body weight and longer disease duration.
Using the WHO criteria (T score < −2.5), the prevalence of osteoporosis
determined by BMD is about 29% in the spine and 12% in the hip in
patients with ankylosing spondylitis, which compares with 2% and 1%
respectively for controls. Although BMD is generally lower in patients with
early disease, with progressive disease, the spine site becomes much less
reliable due to the presence of syndesmophytes and periosteal new bone
formation. In advanced cases, DXA becomes less reliable but using QCT,
bone loss can be shown to continue within the vertebra and hips as well as
an increase in cortical BMD and width.
The epidemiology of fractures in ankylosing spondylitis remains unclear
although vertebral fractures have been most studied. The risk of clinical
vertebral fractures is significantly increased (OR approximately 7.7 95% CI
4.3-12.6) and the cumulative incidence of clinical vertebral fractures is
higher in men (OR 10.7 versus 4.2 in women) and increased especially
during the first 5 years of the disease. The prevalence and incidence of
non-vertebral fractures has been less well studied but in most reports
appears to be about the same as in the control population.
Managing skeletal complications in anklosing spondylitis should include
DXA of the spine and hip early in the disease. In more advanced disease,
spinal DXA is not a useful predictor of fracture. In these circumstances,
QCT should be considered. If a vertebral fracture is suspected, spinal
imaging is required in order to avoid delays in diagnosis and therapy.
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Conventional radiography can visualize bone erosion, sclerosis, joint space
narrowing and new bone formation in sacroiliac joints and the spine, but is
unfortunately not very sensitive in early disease. Diagnosis of ankylosing
spondylitis (AS) is dependent on presence of bilateral moderate or
unilateral severe radiographic sacroiliitis, as part of the modified New York
criteria for AS. This has, until recently (see MRI below), delayed the
diagnosis by 7-10 years. Furthermore, the modified Stokes ankylosing
spondylitis spine score (mSASSS), which is the most sensitive radiographic
method for monitoring structural damage in AS, is not very reproducible
or sensitive to change, so improved methods for structural damage
assessment are highly needed.
MRI has resulted in a major improvement in the evaluation and
management of patients with SpA. Firstly, it permits earlier diagnosis, as
MRI findings of active sacroiliitis form part of the recent ASAS criteria for
axial spondyloarthritis. Secondly, MR Ic a np r o v i d eo b j e c t i v ee v i d e n c eo f
currently active inflammation in patients with SpA. MRI is by far the best
available method for detecting and monitoring inflammation in the spine
and sacroiliac joints, and several validated assessment systems exist. Until
the introduction of MRI, disease activity assessment was restricted to
patient-reported outcomes, such as the Bath ankylosing spondylitis disease
activity index (BASDAI) and functional index (BASFI), because disease
activity could not be assessed in a sensitive manner by biochemical
(mainly C- reactive protein (CRP)) or physical evaluation. Furthermore, MRI
can visualize structural damage (erosion, fat infiltration, syndesmophytes
and ankylosis) in the sacroiliac joint and spine, but the clinical role of MRI
for monitoring structural damage remains to be established.
Finally, certain MRI findings (inflammation at the vertebral corners) have
predictive value with respect to subsequent development of radiographic
syndesmophytes. However, clarification of the prognostic value of MRI in
clinical practice requires further research.
Despite contrast-enhanced Doppler US has been reported to have a high
negative predictive value for the detection of sacroiliitis, the role of US in
assessment of sacroiliac and spine involvement in AS and other types of
axial SpA is minimal.
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Glucocorticoids (GC) are the most potent anti-inflammatory and
immunosuppressive hormones mainly produced by the adrenal glands in
humans.
The central nervous clock system, under the influence of light/dark
alternation, “creates” the internal circadian rhythms and the organisms by
“feeling” these rhythmic external changes, synchronize their physical
activities, including sleep, related nocturnal hormone synthesis and immune
function [1].
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anti-inflammatory and immunosuppressive activities. On the other hand,
the nocturnal pineal hormone melatonin, that rises earlier in the night with
darkness, has been linked to chronic inflammation since at normal to
slightly elevated concentrations stimulate many aspects of the immune/
inflammatory response, especially at the level of macrophages [2].
The immune-supportive role of melatonin and the reduced immune
suppression linked to decreased endogenous GC (due to the chronic
stress of the disease) have been delineated in the context of the
circadian rhythms of immune/inflammatory reaction and related clinical
(morning) symptoms, at least in RA [3].
Therefore, the most advanced approach to optimize the risk-benefit ratio
of long-term low-dose GC treatment is the GC-chronotherapy, using a
modified release (MR) prednisone (release during the night) and following
the circadian rhythms.
In fact in RA, the circadian rhythms of clinical symptoms are more evident
in the early morning hours, since preceded by nocturnal elevated levels of
pro-inflammatory cytokines (i.e.IL-6). Therefore, since prevention of
nocturnal rise of pro-inflammatory cytokines by GC therapy would be
more effective than treating established symptoms in the morning and
might reduce doses and side effects, a MR prednisone was developed,
which releases prednisone approximately four hours after ingestion (i.e., at
approximately 2-3 am when taken at bedtime) [4]. In addition to all
recognized therapeutic effects obtained with conventional prednisone, MR
prednisone was shown to have similar profile of adverse effects but
without additional suppression of hypothalamic-pituitary-adrenal (HPA)
axis [5].
In conclusion, night-time low dose long-term GC therapy in chronic
rheumatic diseases such as RA, is today considered as an “hormonal
replacement therapy” that optimally implement the peripheral
insufficiency of endogenous GC in modulating the immune/inflammatory
reaction.
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